Cemiplimab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Cemiplimab and local guidelines before prescribing.

Immune checkpoint inhibitor

Mechanism

PD-1 inhibitor.

Uses

Cutaneous squamous cell carcinoma, basal cell carcinoma, lung cancer.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Immune-related adverse events, rash, diarrhoea.

Interactions

Immunosuppressants reduce effect.

Contraindications and cautions

Autoimmune disease caution

Monitoring

TFT, LFT

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive

Special advice

Immune toxicity pathway as other checkpoint inhibitors.

More from the textbook: uses, cautions and other points
Where it is discussed in the book